Venglustat for Gaucher disease type 3
One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Gaucher Disease. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Gaucher Disease. Turn any of these off from the link in every email.
The FDA is expected to decide on Venglustat for Gaucher disease type 3 by November 25, 2026, under an NDA from Sanofi.
What is being decided
Sanofi has an NDA under FDA review for Venglustat in Gaucher disease type 3. Oral brain-penetrant therapy for the neurological form of Gaucher disease.
Who this decision matters to
Gaucher disease is a rare inherited lysosomal storage disorder caused by deficiency of the enzyme glucocerebrosidase, resulting in accumulation of fatty substances in the spleen, liver, and bone marrow. This buildup causes bone pain, splenomegaly, anemia, thrombocytopenia, and progressive organ damage. Multiple treatment options including enzyme replacement and substrate reduction therapies are available.
Prevalence: 1 in 40,000 to 60,000 in general population; 1 in 850 among Ashkenazi Jewish population. See our full Gaucher Disease page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Gaucher Disease treatment stands today
Read our full Gaucher Disease treatment summary
Gene therapy and improved disease-modifying therapies are opening new horizons for Gaucher disease management. Clinical trials continue evaluating gene therapy approaches, next-generation enzyme replacement formulations, and novel substrate reduction inhibitors that may offer improved efficacy, dosing convenience, or better tolerability.
The International Collaborative Gaucher Group and Gaucher Disease Support Group maintain trial registries. Genetic counseling helps families understand inheritance patterns and plan for future pregnancies.
If diagnosed with Gaucher disease, work with your metabolic specialist to understand all available treatment options, as newer agents continue to emerge with potentially superior benefits over earlier therapies.
The Gaucher Disease page has every treatment and trial →Meanwhile, 25 Gaucher Disease studies are enrolling
Whatever the FDA decides here, research on Gaucher Disease does not stop. Of these, 8 test a treatment; the others follow patients over time. The most recently updated:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Gaucher Disease. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Gaucher Disease. Turn any of these off from the link in every email.
Frequently asked questions
When will the FDA decide on Venglustat?
The FDA's target date (PDUFA date) for Venglustat in Gaucher disease type 3 is November 25, 2026.
Who disclosed it: Sanofi. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: Sanofi press release
What is Venglustat being reviewed for?
Sanofi submitted an NDA for Venglustat in Gaucher disease type 3.
What to know: Oral brain-penetrant therapy for the neurological form of Gaucher disease.
Is there already an FDA-approved treatment for Gaucher Disease?
Yes. Trial Friend's drug list includes 5 FDA-approved drugs for Gaucher Disease.
Approved: Cerezyme (imiglucerase), Zavesca (miglustat), VPRIV (velaglucerase alfa), Elelyso (taliglucerase alfa), Cerdelga (eliglustat).
Also coming: Venglustat.
Check: the Gaucher Disease page also searches FDA drug labels for approved treatments.
Can I get Venglustat before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 25 Gaucher Disease studies are enrolling now, 8 of them testing a treatment. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Sanofi directly. Registered programs are listed on ClinicalTrials.gov.
How much will Venglustat cost?
Sanofi has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Venglustat decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Sanofi press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.